Department of Life Sciences, School of Pharmacy, International Medical University, Kuala Lumpur, 57000, Malaysia.
Perdana University-Royal College of Surgeons in Ireland, Seri Kembangan, 43400, Selangor, Malaysia.
BMC Complement Altern Med. 2019 Sep 14;19(1):257. doi: 10.1186/s12906-019-2663-9.
Clinacanthus nutans extracts have been consumed by the cancer patients with the hope that the extracts can kill cancers more effectively than conventional chemotherapies. Our previous study reported its anti-inflammatory effects were caused by inhibiting Toll-like Receptor-4 (TLR-4) activation. However, we are unsure of its anticancer effect, and its interaction with existing chemotherapy.
We investigated the anti-proliferative efficacy of polar leaf extracts (LP), non-polar leaf extracts (LN), polar stem extract (SP) and non-polar stem extracts (SN) in human breast, colorectal, lung, endometrial, nasopharyngeal, and pancreatic cancer cells using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, MTT assay. The most potent extracts was tested along with gemcitabine using our established drug combination analysis. The effect of the combinatory treatment in apoptosis were quantified using enzyme-linked immunosorbent assay (ELISA), Annexin V assay, antibody array and immunoblotting. Statistical significance was analysed using one-way analysis of variance (ANOVA) and post hoc Dunnett's test. A p-value of less than 0.05 (p < 0.05) was considered statistical significance.
All extracts tested were not able to induce potent anti-proliferative effects. However, it was found that pancreatic ductal adenocarcinoma, PDAC (AsPC1, BxPC3 and SW1990) were the cell lines most sensitive cell lines to SN extracts. This is the first report of C. nutans SN extracts acting in synergy with gemcitabine, the first line chemotherapy for pancreatic cancer, as compared to conventional monotherapy. In the presence of SN extracts, we can reduce the dose of gemcitabine 2.38-5.28 folds but still maintain the effects of gemcitabine in PDAC. SN extracts potentiated the killing of gemcitabine in PDAC by apoptosis. Bax was upregulated while bcl-2, cIAP-2, and XIAP levels were downregulated in SW1990 and BxPC3 cells treated with gemcitabine and SN extracts. The synergism was independent of TLR-4 expression in pancreatic cancer cells.
These results provide strong evidence of C. nutans extracts being inefficacious as monotherapy for cancer. Hence, it should not be used as a total substitution for any chemotherapy agents. However, SN extracts may synergise with gemcitabine in the anti-tumor mechanism.
人们希望食用角叉菜 Nutans 提取物能比传统化疗更有效地杀死癌症,因此癌症患者会食用角叉菜 Nutans 提取物。我们之前的研究报告称,其抗炎作用是通过抑制 Toll 样受体 4(TLR-4)激活来实现的。然而,我们不确定其抗癌作用及其与现有化疗药物的相互作用。
我们使用噻唑蓝(MTT)比色法检测极性叶提取物(LP)、非极性叶提取物(LN)、极性茎提取物(SP)和非极性茎提取物(SN)在人乳腺癌、结直肠癌、肺癌、子宫内膜癌、鼻咽癌和胰腺癌细胞中的抗增殖作用。使用我们建立的药物组合分析,对最有效的提取物与吉西他滨进行了测试。使用酶联免疫吸附试验(ELISA)、Annexin V 检测、抗体阵列和免疫印迹定量检测联合治疗的细胞凋亡效果。使用单因素方差分析(ANOVA)和事后 Dunnett 检验分析统计显著性。p 值小于 0.05(p<0.05)被认为具有统计学意义。
所有测试的提取物均不能诱导有效的抗增殖作用。然而,我们发现胰腺导管腺癌(PDAC)(AsPC1、BxPC3 和 SW1990)是对 SN 提取物最敏感的细胞系。这是首次报道角叉菜 Nutans SN 提取物与吉西他滨(用于治疗胰腺癌的一线化疗药物)协同作用,与传统的单一疗法相比。在 SN 提取物存在的情况下,我们可以将吉西他滨的剂量减少 2.38-5.28 倍,但仍能保持吉西他滨在 PDAC 中的作用。SN 提取物增强了吉西他滨在 PDAC 中的杀伤作用,通过细胞凋亡实现。在吉西他滨和 SN 提取物处理的 SW1990 和 BxPC3 细胞中,Bax 上调,而 bcl-2、cIAP-2 和 XIAP 水平下调。这种协同作用与胰腺癌细胞中 TLR-4 的表达无关。
这些结果为角叉菜 Nutans 提取物作为癌症单一疗法无效提供了有力证据。因此,它不应该被用作任何化疗药物的完全替代品。然而,SN 提取物可能与吉西他滨在抗肿瘤机制中具有协同作用。